Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Completed · Phase 1

Conditions studied: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma, Metastatic Cancer, Retinoblastoma, Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the safety of delivering intrathecal busulfan in children and adolescents who have refractory CNS cancer and to estimate the maximum tolerated dose of this treatment regimen.

Key facts

Study ID

NCT00006246

Run by

Pediatric Brain Tumor Consortium

People needed

28

Starts

2000-11-01

Last updated by the study team

2009-10-07

Who can join

Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Duke Comprehensive Cancer Center — Durham, North Carolina, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States
• Baylor College of Medicine — Houston, Texas, United States
• Children's Hospital and Regional Medical Center - Seattle — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.